$IMUX
Immunic Inc

2017 Q3 Form 10-Q Financial Statement

#000128077617000080 Filed on August 03, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2017 Q2 2016 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.950M $2.720M $2.690M
YoY Change 6.5% 1.12% -23.8%
% of Gross Profit
Research & Development $9.689M $9.834M $6.858M
YoY Change 29.72% 43.39% -40.6%
% of Gross Profit
Depreciation & Amortization $216.0K $229.0K $490.0K
YoY Change -48.57% -53.27% 49.39%
% of Gross Profit
Operating Expenses $12.64M $12.55M $9.546M
YoY Change 23.44% 31.46% -36.69%
Operating Profit -$12.64M -$12.55M -$9.546M
YoY Change 23.44% 31.46% -36.69%
Interest Expense $190.0K $170.0K $80.00K
YoY Change 137.5% 112.5% 700.0%
% of Operating Profit
Other Income/Expense, Net $158.0K $142.0K $78.00K
YoY Change 159.02% 82.05% -378.57%
Pretax Income -$12.48M -$12.41M -$9.470M
YoY Change 22.59% 31.05% -37.33%
Income Tax
% Of Pretax Income
Net Earnings -$12.48M -$12.41M -$9.468M
YoY Change 22.63% 31.04% -37.32%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$11.77M -$11.71M -$12.14M
COMMON SHARES
Basic Shares Outstanding 42.21M shares 42.21M shares 31.24M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q3 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $66.40M $76.20M $73.60M
YoY Change -2.5% 3.53% 2.36%
Cash & Equivalents $66.39M $76.15M $73.60M
Short-Term Investments
Other Short-Term Assets $1.600M $1.900M $1.800M
YoY Change 14.29% 5.56% -48.57%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $67.96M $78.06M $75.44M
YoY Change -2.17% 3.48% -0.01%
LONG-TERM ASSETS
Property, Plant & Equipment $2.272M $2.430M $3.014M
YoY Change -22.25% -19.38% -28.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $126.0K $182.0K $182.0K
YoY Change 44.83% 0.0% -14.95%
Total Long-Term Assets $2.398M $2.612M $3.196M
YoY Change -20.31% -18.27% -27.79%
TOTAL ASSETS
Total Short-Term Assets $67.96M $78.06M $75.44M
Total Long-Term Assets $2.398M $2.612M $3.196M
Total Assets $70.36M $80.68M $78.63M
YoY Change -2.92% 2.6% -1.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $981.0K $1.076M $887.0K
YoY Change -17.77% 21.31% -3.59%
Accrued Expenses $7.167M $6.147M $3.439M
YoY Change 113.49% 78.74% -61.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.234M $7.292M $4.473M
YoY Change 77.84% 63.02% -55.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $46.00K $46.00K $12.00K
YoY Change -44.58% 283.33% -92.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.234M $7.292M $4.473M
Total Long-Term Liabilities $46.00K $46.00K $12.00K
Total Liabilities $8.280M $7.338M $4.485M
YoY Change 75.68% 63.61% -55.75%
SHAREHOLDERS EQUITY
Retained Earnings -$281.4M -$268.9M -$221.9M
YoY Change 21.23% 21.17% 22.81%
Common Stock $4.000K $4.000K $56.00K
YoY Change 33.33% -92.86% 2700.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $62.08M $73.34M $74.15M
YoY Change
Total Liabilities & Shareholders Equity $70.36M $80.68M $78.63M
YoY Change -2.92% 2.6% -1.55%

Cashflow Statement

Concept 2017 Q3 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income -$12.48M -$12.41M -$9.468M
YoY Change 22.63% 31.04% -37.32%
Depreciation, Depletion And Amortization $216.0K $229.0K $490.0K
YoY Change -48.57% -53.27% 49.39%
Cash From Operating Activities -$9.420M -$10.15M -$8.820M
YoY Change 19.39% 15.08% -41.63%
INVESTING ACTIVITIES
Capital Expenditures -$160.0K -$140.0K -$40.00K
YoY Change -40.74% 250.0% -96.95%
Acquisitions
YoY Change
Other Investing Activities $0.00 $10.00K $80.00K
YoY Change -100.0% -87.5% -33.33%
Cash From Investing Activities -$170.0K -$130.0K $40.00K
YoY Change 240.0% -425.0% -103.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -180.0K -210.0K 4.510M
YoY Change -107.41% -104.66%
NET CHANGE
Cash From Operating Activities -9.420M -10.15M -8.820M
Cash From Investing Activities -170.0K -130.0K 40.00K
Cash From Financing Activities -180.0K -210.0K 4.510M
Net Change In Cash -9.770M -10.49M -4.270M
YoY Change 77.31% 145.67% -73.8%
FREE CASH FLOW
Cash From Operating Activities -$9.420M -$10.15M -$8.820M
Capital Expenditures -$160.0K -$140.0K -$40.00K
Free Cash Flow -$9.260M -$10.01M -$8.780M
YoY Change 21.52% 14.01% -36.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1076000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4656000 USD
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
780000 USD
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Period End Date
DocumentPeriodEndDate
2017-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42207376 shares
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
VITAL THERAPIES INC
dei Trading Symbol
TradingSymbol
VTL
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6147000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9601000 USD
CY2017Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10147000 USD
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
83000 USD
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
90000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
302185000 USD
CY2017Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
342127000 USD
CY2016Q4 us-gaap Assets
Assets
64026000 USD
CY2017Q2 us-gaap Assets
Assets
80675000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
61463000 USD
CY2017Q2 us-gaap Assets Current
AssetsCurrent
78063000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
36000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
130000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83416000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73598000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59991000 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76153000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9818000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
16162000 USD
CY2016Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
92.99
CY2017Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
92.99
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
240620 shares
CY2017Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
240620 shares
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-294000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1401 shares
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6450590 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32143475 shares
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42207376 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32143475 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42207376 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9468000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19057000 USD
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12401000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25002000 USD
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
44000 USD
CY2017Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
69000 USD
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
99000 USD
CY2017Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
46000 USD
CY2016Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
490000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
984000 USD
CY2017Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
229000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
564000 USD
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-1000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
0 USD
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2154000 USD
CY2017Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1997000 USD
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2688000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5487000 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2715000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5774000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-360000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
46000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1797000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1502000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-83000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-28000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
478000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
557000 USD
CY2016Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
75000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
135000 USD
CY2017Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
169000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
266000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64026000 USD
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80675000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5480000 USD
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7292000 USD
CY2016Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
100000 USD
CY2017Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
46000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8835000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
37620000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
131000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-398000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18783000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-21060000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-9468000 USD
us-gaap Net Income Loss
NetIncomeLoss
-19057000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-12407000 USD
us-gaap Net Income Loss
NetIncomeLoss
-25009000 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
78000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
145000 USD
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
142000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
227000 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
9546000 USD
us-gaap Operating Expenses
OperatingExpenses
19202000 USD
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
12549000 USD
us-gaap Operating Expenses
OperatingExpenses
25236000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9546000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-19202000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12549000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-25236000 USD
CY2016Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
226000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
443000 USD
CY2017Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
229000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
483000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
186000 USD
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
183000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
58000 USD
CY2017Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
182000 USD
CY2016Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2017Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
7000 USD
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
44000 USD
CY2017Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
69000 USD
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
979132 USD
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000 USD
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-27000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-39000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
1000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
3000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
20000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
60000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
165000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
405000 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1472000 USD
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1910000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8823000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37679000 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
2000 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
7000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12106000 USD
CY2017Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12577000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2505000 USD
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2430000 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6858000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13715000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9834000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19462000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-243825000 USD
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-268884000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2007000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2419000 USD
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3316639 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
127904 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1356426 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.30
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
73337000 USD
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2015Q2 vtl Maximum Number Of Common Shares That Can Be Issued By Certain Stockholders Under Shelf Registration Statement
MaximumNumberOfCommonSharesThatCanBeIssuedByCertainStockholdersUnderShelfRegistrationStatement
2500000 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4841274 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6068395 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.78
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.79
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
979132 USD
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5922129 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.83
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.43
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.25
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
979132 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11M19D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M5D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y4M21D
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31247069 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30905079 shares
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42207376 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37452655 shares
CY2016Q4 vtl Accrued Clinical Costs
AccruedClinicalCosts
2316000 USD
CY2017Q2 vtl Accrued Clinical Costs
AccruedClinicalCosts
3967000 USD
CY2015Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34500000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
58446000 USD
vtl Change In Stock Option Early Exercise Repurchase Liability
ChangeInStockOptionEarlyExerciseRepurchaseLiability
23000 USD
vtl Change In Stock Option Early Exercise Repurchase Liability
ChangeInStockOptionEarlyExerciseRepurchaseLiability
0 USD
vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
4000 USD
vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
150000 USD
CY2017Q2 vtl Issuance Of Securities Authorized Offering Amount
IssuanceOfSecuritiesAuthorizedOfferingAmount
113100000 USD
CY2015Q2 vtl Issuance Of Securities Authorized Offering Amount
IssuanceOfSecuritiesAuthorizedOfferingAmount
200000000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires us to make certain estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001280776-17-000080-index-headers.html Edgar Link pending
0001280776-17-000080-index.html Edgar Link pending
0001280776-17-000080.txt Edgar Link pending
0001280776-17-000080-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtl-063017xexhibit311.htm Edgar Link pending
vtl-063017xexhibit312.htm Edgar Link pending
vtl-063017xexhibit321.htm Edgar Link pending
vtl-063017xexhibit322.htm Edgar Link pending
vtl-20170630.xml Edgar Link completed
vtl-20170630.xsd Edgar Link pending
vtl-20170630_cal.xml Edgar Link unprocessable
vtl-20170630_def.xml Edgar Link unprocessable
vtl-20170630_lab.xml Edgar Link unprocessable
vtl-20170630_pre.xml Edgar Link unprocessable
vtl-63017x10q.htm Edgar Link pending